


Introduction to ACIP's Adult Respiratory Syncytial Virus Work Group

Camille Kotton, MD
Chair, Adult RSV Work Group

ACIP General Meeting
June 23, 2022



Work Group Membership

ACIP Voting Members

Camille Kotton (chair)

Keipp Talbot

Sarah Long

Ex Officio Members

Rachel Zhang (FDA)

Susan Wollersheim (FDA)

Judy Beeler (FDA)

Sonnie Kim (NIH/NIAID)

CDC Lead

Michael Melgar

Consultants

Robert Atmar (Baylor College of Medicine)

Cynthia Lucero-Obusan (Veterans Health Administration)

Marie Griffin (Vanderbilt University Medical Center)

Tracy Ruckwardt (NIH/NIAID)

Angela Branche (University of Rochester)

Liaisons

Kenneth Schmader (American Geriatric Society)

Shmuel Shoham (American College of Physicians)

Gretchen LaSalle (American Academy of Family Physicians)

April Killikelly (Public Health Agency of Canada)

Michael Hogue (American Pharmacists Association)

CDC Contributors

Respiratory Viruses

Meredith McMorro

Fiona Havers

Mila Prill

Diya Surie

Natalie Thornburg

Aron Hall

Immunization Safety

Anne Hause

Christine Olson

Immunization Services

Neil Murthy

Patricia Wodi

Amy Parker Fiebelkorn

Purpose of the Work Group

- Respiratory syncytial virus (RSV) is a major cause of lower respiratory illness, particularly among infants and children and among older adults and adults with chronic medical conditions.
- RSV vaccine and immuno-prophylaxis development has progressed in the past decade with over 40 candidate vaccines and monoclonal antibodies currently in development.
- Target populations for whom these products are intended include infants and young children, pregnant women, and older adults.
- This WG will consider policy questions related to adult vaccination.

Work Group Activities

- Consider recommendations for use of RSV vaccines in adults:
 - Review the epidemiology and burden of RSV disease in older adults.
 - Review efficacy, immunogenicity, safety, and cost-effectiveness of RSV vaccine(s) in older adults.
 - Provide evidence-based recommendations regarding routine use of RSV vaccine(s) in older adults.
 - Identify areas in need of further research for informing potential future vaccine recommendations, including risk-based indications for adults with underlying medical conditions younger than the age for a routine immunization recommendation.

Adult RSV Vaccine Products Expected to be Reviewed by the WG

- *GSK*
 - Protein-based + adjuvant
- *Pfizer*
 - Protein-based
- *Janssen Pharmaceutical*
 - Adenovirus vector + soluble protein
- *Moderna*
 - mRNA
- *Bavarian Nordic*
 - Vaccinia vector

Tentative ACIP timeline*

| 2022 | | 2023 | | |
|--|--|---|---|------------------------------------|
| June | October | February | June | October |
| Epidemiology and burden of RSV disease | 1–2 manufacturer presentations GRADE for 1–2 vaccine products | 1–2 manufacturer presentations GRADE for 1–2 vaccine products Cost effectiveness EtR for 1–2 vaccine products Policy options for 1–2 products | ACIP votes on 1–2 vaccine products GRADE & EtR for 1–2 vaccine products Policy options for 1–2 products | ACIP votes on 1–2 vaccine products |

***Subject to change**

Agenda: Thursday June 23, 2022

- RSV virion & vaccine products Dr. Natalie Thornburg (CDC)
- Epidemiology of RSV in children Dr. Meredith McMorro (CDC)
- Epidemiology of RSV in adults Dr. Fiona Havers (CDC)
- Safety and efficacy of nirsevimab Dr. Christian Felter (Sanofi)

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

